{"id":"W2093786954","doi":"10.1097/qad.0000000000000519","title":"Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials","year":2014,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada); University of Toronto; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Cilag; GlaxoSmithKline; ViiV Healthcare; Gilead Sciences; National Institute of Allergy and Infectious Diseases; Pfizer; Bristol-Myers Squibb","keywords":"Dolutegravir; Abacavir; Medicine; Emtricitabine; Darunavir; Raltegravir; Internal medicine; Efavirenz; Ritonavir; Lamivudine; Confidence interval; Integrase inhibitor; Clinical endpoint; Randomized controlled trial; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Hepatitis B virus","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002968381,0.0003999295,0.002870119,0.0006764675,0.00004268418,0.00001439213,0.0001183568,0.0002110716,0.0006176829],"category_scores_gemma":[0.002052732,0.0002665663,0.0004700962,0.0005942412,0.0001383627,0.00007639217,0.00006319952,0.0001517377,0.0002635643],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005186863,"about_ca_system_score_gemma":0.0001701145,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003847146,"about_ca_topic_score_gemma":0.0004067043,"domain_scores_codex":[0.9963933,0.001036362,0.001360033,0.0004351324,0.0003358595,0.0004393736],"domain_scores_gemma":[0.9958891,0.003100431,0.0003656822,0.0004281763,0.00006319349,0.0001533978],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.02625524,0.001647373,0.9457659,0.00005107613,0.001064395,0.00006562019,0.003156273,0.000009431694,0.001190225,0.001450884,0.0008316397,0.01851193],"study_design_scores_gemma":[0.6981341,0.0008513803,0.2850629,0.000449121,0.001195677,0.00001840083,0.00008418379,0.0001588544,0.008576733,0.001455018,0.003599449,0.0004142339],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918729,0.0003024491,0.00009633684,0.0007542676,0.0001381445,0.00255282,0.00003159004,0.00005784652,0.004193617],"genre_scores_gemma":[0.9912253,0.0001716474,0.002010269,0.00005713684,0.00008281371,0.0002998019,0.0003884987,0.00003766029,0.005726888],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6718788,"threshold_uncertainty_score":0.9999787,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03121098539188963,"score_gpt":0.3000794909422271,"score_spread":0.2688685055503375,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}